Cat. No.: DAB-0011918
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG2a |
| Host Species | Mouse |
| Reactivity | Human, Mouse, Rat |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the carboxy terminus of human Cox2 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | PTGS2 |
| UniProt No. | P35354 |
| Gene ID | 5743 |
| Gene Description | Cyclooxygenase1 and cyclooxygenase2, family members with 60% homology in humans, catalyze prostaglandin production from arachidonic acid. While Cox1 expression is constitutive in most tissues, Cox2 expression is induced by lipopolysaccharide and peptidoglycan. PGN activates Ras, leading to phosphorylation of Raf at Ser338 and Erk1/2 at Tyr204. The activation of MAP kinase signaling results in subsequent activation of IKKα/β, phosphorylation of IκBα at Ser32/36, and NF-κB activation. Finally, activation of the transcription factor NF-κB is responsible for the induction of Cox2 expression. Investigators have shown that LPS and PGN induce the clinical manifestations of arthritis and bacterial infections, such as inflammation, fever, and septic shock. Research studies have indicated that Cox1 and Cox2 may also play a role in the neuropathology of Alzheimer's disease by potentiating γ-secretase activity and β-amyloid generation. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
